Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico.

Background: The treatment of multiple myeloma (MM) has become costly and difficult to access for patients living in low-income to middle-income countries.

Methods: The current retrospective study included 148 patients in Mexico with newly diagnosed MM, and was performed to compare the outcomes of patients with and without access to novel agents. The records of 77 patients admitted to a public hospital (PubC) and 71 patients cared for within private health systems (PrivC) from November 2007 to July 2016 were reviewed.

[New anticoagulants: dabigatran, rivaroxaban and apixaban].

To date, the most widely used drugs in our anticoagulation clinics are acenocoumarin and warfarin, which belong to the category of vitamin K antagonists (VKA). They have about 70 years of use in the clinic, with proven efficacy for various thrombotic diseases, but also with known problems of variability and dietary and drug interactions. In hospital thromboprophylaxis, the most widely used anticoagulant is enoxaparin, a low molecular weight heparin (LMWH).